In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including:

Clinical outcomes and limitations of first-generation KRAS G12C inhibitors
Key unmet needs, including primary and acquired resistance
Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy

Presenters:

Luis Paz-Ares, MD, PhD
Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Madrid, Spain

Christine Bestvina, MD
Associate Professor
University of Chicago Medicine
Division of Medicine
Section of Hematology/Oncology
University of Chicago Medicine
Chicago, Illinois

Link to full program:
https://bit.ly/4rhoUuN

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions